EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation
Mené sur 1 313 patients atteints d'un cancer du poumon non à petites cellules de stade avancé, cet essai de phase III compare l'efficacité, en fonction du statut tumoral EGFR et du point de vue de la survie sans progression et de la survie globale, et la toxicité de l'ajout du cétuximab à une chimiothérapie combinant carboplatine et paclitaxel, avec ou sans bévacizumab
Lung cancer is diagnosed in 1·8 million people worldwide each year. About 40% of these patients will present with advanced non-small-cell lung cancer (NSCLC). Therapeutic advances in advanced NSCLC include targeted therapies directed against EGFR.1 EGFR expression on the surface of tumour cells has been studied as a therapeutic target for monoclonal antibodies.2 Cetuximab treatment improved survival of patients when added to platinum-based first-line chemotherapy compared with chemotherapy alone and this benefit had a hazard ratio (HR) of 0·77 (95% CI 0·64–0·93) in patients with squamous cell NSCLC.
The Lancet Oncology , commentaire, 2016